Il mare unisce ciò che la terra divide. Antropologie dai mari del sud.

L'intero dossier monografico "Il mare unisce ciò che la terra divide. Antropologie dai mari del Sud", a cura di Matteo Aria e Francesco Lattanzi apre a prospettive antropologiche inedite per rileggere i mari come luoghi di connessione, di condivisione e di possibili rotte che vanno oltre le ricorrenti narrazioni delle chiusure identitarie

P477: PHENOTYPICALLY-DEFINED STAGES OF LEUKEMIA ARREST PREDICT MAIN DRIVER MUTATIONS SUBGROUPS, AND OUTCOME IN ACUTE MYELOID LEUKEMIA

Classifications of acute myeloid leukemia (AML) patients rely on morphologic, cytogenetic, and molecular features. Here we have established a novel flow cytometry-based immunophenotypic stratification showing that AML blasts are blocked at specific stages of differentiation where features of normal myelopoiesis are preserved. Six stages of leukemia differentiation-arrest categories based on CD34, CD117, CD13, CD33, MPO, and HLA-DR expression were identified in two independent cohorts of 2087 and 1209 AML patients. Hematopoietic stem cell/multipotent progenitor-like AMLs display low proliferation rate, inv(3) or RUNX1 mutations, and high leukemic stem cell frequency as well as poor outcome, whereas granulocyte–monocyte progenitor-like AMLs have CEBPA mutations, RUNX1-RUNX1T1 or CBFB-MYH11 translocations, lower leukemic stem cell frequency, higher chemosensitivity, and better outcome. NPM1 mutations correlate with most mature stages of leukemia arrest together with TET2 or IDH mutations in granulocyte progenitors-like AML or with DNMT3A mutations in monocyte progenitors-like AML. Overall, we demonstrate that AML is arrested at specific stages of myeloid differentiation (SLA classification) that significantly correlate with AML genetic lesions, clinical presentation, stem cell properties, chemosensitivity, response to therapy, and outcome

L’ajout de la lomustine bénéficie aux leucémies myéloïdes aiguës du sujet âgé avec cytogénétique non-défavorable et d’un profil moléculaire à haut risque de l’European Leukemia Net 2017

# 07-03International audienc